Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

University Hospital, Strasbourg, France100 enrolled

Overview

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Cystic Fibrosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient (≥ 18 years old) * With confirmed cystic fibrosis * Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center Exclusion Criteria: * Patients who have undergone a double lung transplant for cystic fibrosis.

Locations (1)

Service de Pneumologie - CHU de Strasbourg - France

Strasbourg, France

Outcomes

Primary Outcomes

Prevalence of smoking in adults with cystic fibrosis

The proportion of adults with cystic fibrosis who smoke: Example: If 10 out of 100 adults with cystic fibrosis smoke, then the prevalence of smoking in this group is 10%.

Time frame: Up to 12 months